For millions of people who have spent years being told their symptoms were a simple “cyst problem,” a new name could finally change how the medical world — and the world at large — treats them. Polycystic Ovary Syndrome, long known as PCOS, is officially being renamed Polyendocrine Metabolic Ovarian Syndrome, or PMOS. Researchers say the shift is about far more than terminology: it’s about dismantling a decades-long stigma that has shaped diagnosis, treatment and self-image.
Why the PCOS Name Change Matters Now
The change follows more than a decade of work led by professor Helena Teede of Monash University, alongside professor Terhi Piltonen of Oulu University and 56 patient and professional organizations worldwide.
The old name centered a single feature —“ovarian cysts” — that isn’t even accurate. Those “cysts” are actually immature follicles, and they aren’t the defining feature of the condition. Yet for years, the label reduced a complex endocrine and metabolic disorder to a reproductive footnote, fueling the assumption that PCOS only matters for people trying to conceive.
“By calling this condition polycystic ovary, we’re missing the big picture,” Dr. Alla Vash-Margita, associate professor of obstetrics, gynecology and reproductive sciences at Yale University, told CNN. “There was a lot of stigma and myth related to this name. People thought they have large cysts, which they do not have.”
How the New Name PMOS Works to Reduce Stigma
PMOS — Polyendocrine Metabolic Ovarian Syndrome — was selected to reflect what the condition actually is: a systemic hormonal and metabolic disorder that affects skin, hair, weight, energy, mental health and fertility. Symptoms such as acne, weight gain, irregular periods and excess hair growth have often been treated as personal failings rather than recognized medical symptoms.
“The agreed principles of the new name included patient benefit, scientific accuracy, ease of communication, avoidance of stigma, cultural appropriateness and accompanying implementation,” Teede said, per the Endocrine Society. “This change was driven with and for those affected by the condition and we are proud to have arrived at a new name that finally accurately reflects the complexity of the condition. Make no mistake, this is a landmark moment that will lead to desperately needed worldwide advancements in clinical practice and research.”
Piltonen added that the renaming had to work across borders. “It was essential that the new name was scientifically correct but also considered across diverse cultural contexts to avoid certain reproductive terms that could heighten stigma and be harmful for women in some countries,” she said.
How Researchers Chose PMOS as the New Name
The research, published in The Lancet, drew on responses from 14,360 patients and multidisciplinary healthcare professionals across the globe. Researchers used iterative international surveys, modified Delphi consensus methods and nominal group workshops to weigh scientific accuracy, clarity, cultural appropriateness, feasibility and stigma reduction.
Marketing and implementation analyses tested whether the new name could realistically be adopted across healthcare systems, medical education and public communication. PMOS emerged as the consensus choice — a name that emphasizes endocrine and metabolic features without erasing the reproductive ones.
What Patients Say About the PCOS Name Change
For patients, the shift is personal. Lorna Berry, an Australian woman with PMOS who took part in the study, said the renaming is overdue recognition.
“This is about accountability and progress,” Berry said. “It is about my daughters, their daughters and the countless women yet to be born. We deserve clarity, understanding and equitable healthcare from the very beginning.”
Advocates hope the new terminology will encourage earlier diagnosis, push clinicians to take whole-body symptoms seriously and validate the experiences of the millions of people who have long felt dismissed under the PCOS label.
